DuPont completes construction of state-of-the-art probiotics facility in the US

USA – DuPont has announced that it has completed construction of a new state-of-the-art probiotics’ fermentation facility in the US to expand its capacity in probiotics production.

Located at DuPont Rochester, New York facility, DuPont said the unit is set to increase probiotic capacity by 70% to enable it to meet the growing consumer demand for healthy food products as well as dietary supplements.

The fermentation facility, said to be the largest in the world will serve as a crucial resource in propagating bacteria and enabling high potency, stability and efficacy of probiotics, said DuPont.

The investment is part of the US$100 million multiphase program to expand probiotics capacity and increase capabilities in delivering high-quality, clinically documented probiotics to dietary supplement and food and beverage manufacturers.

“Completing the construction on our new fermentation unit marks a major milestone in delivering essential innovations for our customers and achieving our ambitious probiotics growth plans,” said Matthias Heinzel, President, DuPont Nutrition & Health.

“Today, we are witnessing a significant rise in demand for probiotics as consumers make health and wellness a daily priority.

“We are proud to continue to deliver on our commitment to invest in this fast-growing segment, which can also enable sustainable growth for our customers around the world.

The fermentation unit is already fully operational, optimizing DuPont’s production capability and according to the company, it enables faster product and service delivery to customers and market.

It will serve as a crucial resource in propagating bacteria and enabling high potency, stability and efficacy of probiotics.

DuPont’s probiotics portfolio offers a wide range of clinically documented strains including DuPont™ Danisco® portfolio which supports digestive health, immune health and women’s health.

As part of the larger microbiome investment strategy, the company is leveraging its probiotics platform for the development of human milk oligosaccharides (HMOs).

DuPont has also announced that it has completed a probiotics capacity expansion at its Madison, Wisconsin, facility.

The investment included upgrading equipment and increasing the pace of new product development and improvement of delivery times on pilot material for clinical trials and customer evaluations.